Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Investments: 2021-2024

Historic Long-Term Investments for Zevra Therapeutics (ZVRA) over the last 3 years, with Dec 2024 value amounting to $6.0 million.

  • Zevra Therapeutics' Long-Term Investments rose 405.57% to $30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year increase of 405.57%. This contributed to the annual value of $6.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Long-Term Investments is $6.0 million, which was down 69.95% from $20.0 million recorded in FY2022.
  • In the past 5 years, Zevra Therapeutics' Long-Term Investments registered a high of $20.0 million during FY2022, and its lowest value of $6.0 million during FY2024.
  • Over the past 2 years, Zevra Therapeutics' median Long-Term Investments value was $13.0 million (recorded in 2022), while the average stood at $13.0 million.
  • Data for Zevra Therapeutics' Long-Term Investments shows a peak YoY soared of 33.94% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows Zevra Therapeutics' Long-Term Investments stood at $14.9 million in 2021, then skyrocketed by 33.94% to $20.0 million in 2022, then reached $6.0 million in 2024.